Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
By S. Kehoe, J. Hook, M. Nankivell, G. Jayson, H. Kitchener, T. Lopes, D. Luesley, T. Perren, S. Bannoo, Monica Mascarenhas and 7 more. The Lancet, 2015
1,261 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/65fa11887d2db6de263d413e6a7473bd95a0515d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Reproductive Medicine
Citations in the corpus
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (2019, background): “Grade 5 adverse events occurring within 30 days of the last dose of a trial drug were reported in 21 patients (<2% overall; 6 patients in the control group, 7 in the veliparib-combination-only group, and 8 in the veliparib-throughout group) and included small-intestinal obstruction (in 2 patients), ”
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, positive): “The EORTC55971 trial [177] and the CHORUS trial [178] showed a similar PFS and OS for patients with stage IIIC or IV disease receiving NACT and interval debulking surgery (IDS) compared with UDS.”